In the ALTER0303 trial, anlotinib was well tolerated as third-line or further therapy and significantly improved PFS and OS in both EGFR-mutated and EGFR-wild-type patients with advanced NSCLC [19]. Here, EGFR is linked to non-small cell lung carcinoma.